Ravi Makwana
Internal Medicine · Easton, PANPI 1174732861
Payments from drug & device makers
Across 117 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$281
- Lilly USA, LLC$219
- Novo Nordisk$196
- Eisai Inc.$124
- Amarin Pharma, Inc.$115
- Amgen$114
- plus $569 from 16 others
What the payments were for
- Food & beverage$1,60599%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $281 |
| Lilly USA, LLC | 20 | $219 |
| Novo Nordisk | 15 | $196 |
| Eisai Inc. | 1 | $124 |
| Amarin Pharma, Inc. | 7 | $115 |
| Amgen | 8 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $99 |
| Pfizer | 5 | $74 |
| Boehringer Ingelheim | 4 | $72 |
| Astellas Pharma US Inc | 3 | $58 |
| AbbVie | 3 | $38 |
| Merck | 3 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Abbott | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$124
How this compares
$1,619 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $14,170 |
| Oseltamivir Phosphate | 133 | $9,009 |
| LinzessLinaclotide | 12 | $6,912 |
| Memantine Hcl ErMemantine Hcl | 12 | $2,042 |
| Levetiracetam | 24 | $1,398 |
| Pantoprazole Sodium | 19 | $1,049 |
| Mirtazapine | 19 | $934 |
| Quetiapine Fumarate | 25 | $621 |
| Baclofen | 26 | $599 |
| Gabapentin | 36 | $589 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 12 | $503 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 12 | $447 |
| Carvedilol | 26 | $444 |
| Levothyroxine Sodium | 43 | $407 |
| Pravastatin Sodium | 18 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $14,17047 claims |
| AbbVieLinzess | $38 | $6,91212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Easton
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.